A Next Generation Assistive Homologous Recombination Deficiency Assay
Comprehensive Genomic Insights
Analyzes 50+ genes, detecting SNVs, INDELs, CNVs, and structural variants
Advanced HRD Scoring
Provides HRD scores with LOH, TAI, and LST for precise tumor profiling
AI Powered Reporting
Utilizes iCARE™ for accurate, dynamic AI-powered reports
Supports PARP inhibitors and platinum-based therapies for improved outcomes
Optimized Treatment Guidance
What is HRD and Why It Matters?
HRD refers to a defect in the ability of cells to repair DNA double-strand breaks through homologous recombination.
Commonly seen in cancers such as breast, ovarian, pancreatic, and prostate.
What is HRD (Homologous Recombination Deficiency)?
HRD refers to a defect in the ability of cells to repair DNA double-strand breaks through homologous recombination.
Commonly seen in cancers such as breast, ovarian, pancreatic, and prostate.
Why HRD: Some key concerns in ovarian cancer treatment
Figure. While 50% of High-grade serous ovarian carcinoma (HGSOC) samples have a positive HRD status, several tumors are attributed by factors beyond BRCA mutations
Defects in the homologous recombination repair pathway
A Literature evidence
Types of Genomic Scars included in OncoHRD®
Why OncoHRD®?
A cutting-edge test specifically designed to detect homologous recombination deficiency (HRD) in solid tumors.
This innovative NGS-based assay offers essential insights to guide the use of PARP inhibitors and platinum-based chemotherapy, ultimately aiming to improve patient outcomes.
Important Features of OncoHRD®
A comprehensive panel of 50+ genes covering all types of genomic alterations such as single nucleotide variants (SNVs), small insertions and deletions (INDELs), copy number variation(CNV), and large structural variants.
Includes an aggregated Homologous Recombination Deficiency (HRD) score along with Loss of Heterozygosity (LOH), Telomeric Allelic Imbalance (TAI), Large-scale transition (LST).
Enables Artificial Intelligence, AI-powered dynamic reporting through iCARE™
Who Should Consider the OncoHRD® Test?
Patients with a Family History of Cancer
Patients with Advanced Cancers
Patients Seeking Personalized Therapy
HRD testing is applicable to a variety of cancers, including:
Breast Cancer: Especially useful for BRCA-mutated or triple-negative breast cancers.
Ovarian Cancer: A key predictor for treatment with PARP inhibitors.
Prostate Cancer: Helps identify those who may benefit from targeted treatments.
Pancreatic Cancer: Guiding the use of targeted therapies in case of HRD positive cases.
